Editorial

Improving uptake of MMR vaccine

BMJ 2008; 336 doi: 10.1136/bmj.39503.508484.80 (Published 3 April 2008)
Cite this as: BMJ 2008;336:729

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Peter McIntyre, director,
  2. Julie Leask, research fellow
  1. 1National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead, NSW 2145, Australia
  1. PeterM{at}chw.edu.au

    Recognising and targeting differences between population groups are the priorities

    Almost a decade since the original report suggesting a link between the combined measles, mumps, and rubella (MMR) vaccine and autism or inflammatory bowel disease, we now have overwhelming evidence to refute such a link.1 Some people, however, still refuse to have their children vaccinated for MMR, and sometimes replace the combined vaccine with single antigen vaccines. In the accompanying study, Pearce and colleagues report uptake of the combined MMR vaccine and single antigen vaccines and they discuss the factors influencing uptake in a three year follow-up of the UK millennium cohort.2

    Low MMR vaccine coverage is not a trivial matter, because the accumulation of unvaccinated children will increase the risk of measles outbreaks. Confirmed cases of measles in England and Wales rose from 56 in 1998 to 971 in 2007 (figure⇓).3 In the United Kingdom, coverage for MMR at 24 months is lower than for other vaccines (85% versus about 94%). …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular